Testing a pig model for liver cancer treatments
Official title: Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development
Funded at Sus Clinicals, INC. · NIH-10931506 · Data updated 2026-11-12
This study is testing a special type of pig that has been genetically modified to develop liver cancer like humans do, to help find better treatments for people with liver cancer by seeing how different genetic changes respond to targeted therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sus Clinicals, INC. NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,035,724 |
| NIH project number | 5R44CA285034-02 |
| Project ID | NIH-10931506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma who may benefit from targeted therapies.
✕Less likely to help
Patients with liver cancer types that do not share genetic similarities with the Oncopig model may not benefit from this research.
What this research studies
This research aims to validate a genetically modified pig model that mimics human liver cancer, specifically hepatocellular carcinoma (HCC). By using advanced techniques like CRISPR to induce specific genetic mutations, the study will evaluate personalized therapies delivered directly to the tumor site. This approach focuses on understanding how different genetic profiles respond to targeted treatments, which could lead to more effective therapies for patients with HCC. The research is crucial as HCC is a common and aggressive cancer, highlighting the need for innovative treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with liver cancer.
How similar studies have gone: Previous research using genetically modified animal models has shown promise in developing targeted cancer therapies, suggesting a potential for success in this approach.
Where this research is happening
-
Sus Clinicals, INC.
Cincinnati, United States Active
Researchers
- Principal investigator: Schachtschneider, Kyle — Sus Clinicals, INC.
- Study coordinator: Schachtschneider, Kyle
Related research
Other NIH-funded projects on the same topics.
-
Role of metabolic stress in NASH-related liver cancer
This grant explores how metabolic stress linked to NASH may drive liver cancer and looks for ways to interrupt that process to help patients.
-
Neoadjuvant Immunotherapy Platform for Hepatocellular Carcinoma
A Johns Hopkins study will test immune-based therapy given before surgery to shrink liver cancer and help prevent recurrence.
-
How overeating and metabolic stress drive NASH-related liver cancer
This research looks at how excess nutrition and cell stress change liver metabolism and push NASH (fatty liver disease) toward liver cancer, with the goal of finding points to stop that process.
-
Using immunotherapy before surgery to improve outcomes in liver cancer
This study is looking at how giving immunotherapy before surgery can help boost the immune system's ability to fight liver cancer, and it's for patients with hepatocellular carcinoma who are preparing for surgery.
-
Investigating how metabolic stress contributes to liver cancer development
This study is looking at how extra weight and changes in metabolism might affect the growth of liver cancer in people with fatty liver disease, and it aims to find ways to slow down or prevent this cancer from getting worse.
-
Using advanced imaging to better understand liver cancer
This study is looking at new ways to spot and treat liver cancer using advanced imaging techniques, which could help doctors understand your cancer better and find the best treatment just for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.